Patents by Inventor Lillian Skidmore

Lillian Skidmore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified FGF-21 polypeptides with non-naturally encoded amino acids
    Patent number: 11993637
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: May 28, 2024
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES
    Publication number: 20230348547
    Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.
    Type: Application
    Filed: December 22, 2022
    Publication date: November 2, 2023
    Inventors: Anna-Maria A. HAYS PUTNAM, Nick KNUDSEN, Thea NORMAN, Alan KODER, Vadim KRAYNOV, Lillian SKIDMORE, Peter C. CANNING
  • Modified bovine G-CSF polypeptides and their uses
    Patent number: 11542310
    Abstract: Modified bovine G-CSF polypeptides and uses thereof are provided.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: January 3, 2023
    Assignees: Ambrx, Inc., Elanco US Inc.
    Inventors: Anna-Maria A. Hays Putnam, Nick Knudsen, Thea Norman, Alan Koder, Vadim Kraynov, Lillian Skidmore, Peter C. Canning
  • COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES
    Publication number: 20220411469
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: April 28, 2022
    Publication date: December 29, 2022
    Applicant: Ambrx, Inc.
    Inventors: Zhenwei MIAO, Kyle ATKINSON, Sandra BIROC, Timothy BUSS, Melissa NEAL, Vadim KRAYNOV, Robin MARSDEN, Jason PINKSTAFF, Lillian SKIDMORE, Ying SUN, Agnieszka SZYDLIK, Delia Ianina LOPEZ DE VALENTA
  • Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
    Patent number: 11420999
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: August 23, 2022
    Assignee: Ambrx, Inc.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
  • COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES
    Publication number: 20210277056
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: January 5, 2021
    Publication date: September 9, 2021
    Applicant: Ambrx, Inc.
    Inventors: Zhenwei MIAO, Kyle ATKINSON, Sandra BIROC, Timothy BUSS, Melissa NEAL, Vadim KRAYNOV, Robin MARSDEN, Jason PINKSTAFF, Lillian SKIDMORE, Ying SUN, Agnieszka SZYDLIK, Delia Ianina LOPEZ DE VALENTA
  • MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES
    Publication number: 20210261637
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: February 2, 2021
    Publication date: August 26, 2021
    Inventors: Thomas P. CUJEC, Roberto MARIANI, Anna-Maria A. HAYS PUTNAM, William M. KEEFE, Nick KNUDSEN, Lillian SKIDMORE, Jason PINKSTAFF, Vadim KRAYNOV
  • PEGYLATED PORCINE INTERFERON AND METHODS OF USE THEREOF
    Publication number: 20210177980
    Abstract: Disclosed herein are porcine interferon alpha variants (pINF-?) comprising a synthetic amino acid at select locations in pINF-? and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pINF-? variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 17, 2021
    Inventors: Peter Connor CANNING, Nickolas KNUDSEN, Lillian SKIDMORE
  • Pegylated porcine interferon and methods of use thereof
    Patent number: 10960080
    Abstract: Disclosed herein are porcine interferon alpha variants (pIFN-?) comprising a synthetic amino acid at select locations in pIFN-? and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pIFN-? variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: March 30, 2021
    Assignees: Elanco US Inc., Ambrx, Inc.
    Inventors: Peter Connor Canning, Nickolas Knudsen, Lillian Skidmore
  • Modified FGF-21 polypeptides and their uses
    Patent number: 10961291
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: March 30, 2021
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
    Patent number: 10954270
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: March 23, 2021
    Assignee: Ambrx, Inc.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
  • MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES
    Publication number: 20200031894
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: June 17, 2019
    Publication date: January 30, 2020
    Inventors: Thomas P. CUJEC, Roberto MARIANI, Anna-Maria A. HAYS PUTNAM, William M. KEEFE, Nick KNUDSEN, Lillian SKIDMORE, Jason PINKSTAFF, Vadim KRAYNOV
  • Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
    Patent number: 10377805
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: August 13, 2019
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • PEGYLATED PORCINE INTERFERON AND METHODS OF USE THEREOF
    Publication number: 20190192673
    Abstract: Disclosed herein are porcine interferon alpha variants (pINF-?) comprising a synthetic amino acid at select locations in pINF-? and a one or two amino acid insertion in the N-terminus after removal of the signal peptide. The pINF-? variants can further be pegylated. Methods of making and administering these compounds to treat virus infections in pigs and formulations comprising the variants are also provided.
    Type: Application
    Filed: June 16, 2017
    Publication date: June 27, 2019
    Inventors: Peter Connor CANNING, Nickolas KNUDSEN, Lillian SKIDMORE
  • MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES
    Publication number: 20180298073
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: April 13, 2018
    Publication date: October 18, 2018
    Inventors: Thomas P. CUJEC, Roberto MARIANI, Anna-Maria A. HAYS PUTNAM, William M. KEEFE, Nick KNUDSEN, Lillian SKIDMORE, Jason PINKSTAFF, Vadim KRAYNOV
  • Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
    Patent number: 9975936
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: May 22, 2018
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, William M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES
    Publication number: 20180009845
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 11, 2018
    Applicant: Ambrx, Inc.
    Inventors: Zhenwei Maio, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jaosn Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Lanina Lopez De Valenta
  • Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
    Patent number: 9796754
    Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: October 24, 2017
    Assignee: Ambrx, Inc.
    Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
  • Modified FGF-21 Polypeptides and Their Uses
    Publication number: 20170096463
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Application
    Filed: October 13, 2016
    Publication date: April 6, 2017
    Inventors: Thomas P. CUJEC, Roberto Mariani, Anna-Maria A. Hays Putnam, Wiliam M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov
  • Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
    Patent number: 9517273
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: December 13, 2016
    Assignee: AMBRX, INC.
    Inventors: Thomas P. Cujec, Roberto Mariani, Anna-Maria A. Hays Putnam, Wiliam M. Keefe, Nick Knudsen, Lillian Skidmore, Jason Pinkstaff, Vadim Kraynov